Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Mar 4

PMID 32121574

Citations 79

Authors

Masahiro Kamata

Yayoi Tada

Affiliations

Soon will be listed here.

Abstract

Psoriasis is a chronic inflammatory skin disease characterized by scaly indurated erythema. It impairs patients' quality of life enormously. It has been recognized not only as a skin disease but as a systemic disease, since it also causes arthritis (psoriatic arthritis) and mental disorders. Furthermore, an association with cardiovascular events is indicated. With the advent of biologics, treatment of psoriasis dramatically changed due to its high efficacy and tolerable safety. A variety of biologic agents are available for the treatment of psoriasis nowadays. However, characteristics such as rapidity of onset, long-term efficacy, safety profile, and effects on comorbidities are different. Better understanding of those characteristic leads to the right choice for individual patients, resulting in higher persistence, longer drug survival, higher patient satisfaction, and minimizing the disease impact of psoriasis. In this paper, we focus on the efficacy and safety profile of biologics in psoriasis patients, including plaque psoriasis and psoriatic arthritis. In addition, we discuss the impact of biologics on comorbidities caused by psoriasis.

Citing Articles

Osteopontin promotes keratinocyte proliferation by G0/G1 cell cycle arrest in psoriasis.

Tang S, Hu H, Liu X, Liao Y, Zhang K, Wang Z Arch Dermatol Res. 2025; 317(1):519.

PMID: 40035859 DOI: 10.1007/s00403-025-04008-1.

Ten-Year Persistence of Biologic Drugs in Psoriasis and Its Relationship with Pharmacogenetic Biomarkers.

Rodriguez-Lopez A, Martinez-Sendino M, Prieto-Perez R, Soria-Chacartegui P, Gonzalez-Iglesias E, Aparicio-Dominguez M Biomedicines. 2025; 13(1.

PMID: 39857589 PMC: 11762171. DOI: 10.3390/biomedicines13010005.

Refractory psoriatic arthritis: emerging concepts in whole process management.

Xu H, Wang Z, Xu L, Su Y Clin Rheumatol. 2025; 44(2):583-590.

PMID: 39808234 DOI: 10.1007/s10067-024-07267-x.

Single-Cell Sequencing and Machine Learning Integration to Identify Candidate Biomarkers in Psoriasis: .

Zhou X, Ning J, Cai R, Liu J, Yang H, Bai Y J Inflamm Res. 2024; 17:11485-11503.

PMID: 39735895 PMC: 11681806. DOI: 10.2147/JIR.S492875.

Electrostimulation: A Promising New Treatment for Psoriasis.

Zuo Z, Wang Y, Fang Y, Wang Z, Yang Z, Jia B Int J Mol Sci. 2024; 25(23).

PMID: 39684717 PMC: 11641613. DOI: 10.3390/ijms252313005.

References

Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, Virgili A . Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol. 2005; 125(1):61-7. DOI: 10.1111/j.0022-202X.2005.23681.x. View

Griffiths C, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A . Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015; 386(9993):541-51. DOI: 10.1016/S0140-6736(15)60125-8. View

Gordon K, Blauvelt A, Papp K, Langley R, Luger T, Ohtsuki M . Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016; 375(4):345-56. DOI: 10.1056/NEJMoa1512711. View

Blauvelt A, Gooderham M, Iversen L, Ball S, Zhang L, Agada N . Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). J Am Acad Dermatol. 2017; 77(5):855-862. DOI: 10.1016/j.jaad.2017.06.153. View

Ikumi K, Odanaka M, Shime H, Imai M, Osaga S, Taguchi O . Hyperglycemia Is Associated with Psoriatic Inflammation in Both Humans and Mice. J Invest Dermatol. 2019; 139(6):1329-1338.e7. DOI: 10.1016/j.jid.2019.01.029. View

Gisondi P, Del Giglio M, Francesco V, Zamboni M, Girolomoni G . Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr. 2008; 88(5):1242-7. DOI: 10.3945/ajcn.2008.26427. View

Strober B, Gooderham M, de Jong E, Kimball A, Langley R, Lakdawala N . Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Am Acad Dermatol. 2017; 78(1):70-80. DOI: 10.1016/j.jaad.2017.08.051. View

Gallais Serezal I, Classon C, Cheuk S, Barrientos-Somarribas M, Wadman E, Martini E . Resident T Cells in Resolved Psoriasis Steer Tissue Responses that Stratify Clinical Outcome. J Invest Dermatol. 2018; 138(8):1754-1763. DOI: 10.1016/j.jid.2018.02.030. View

Araujo E, Englbrecht M, Hoepken S, Finzel S, Kampylafka E, Kleyer A . Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin Arthritis Rheum. 2018; 48(4):632-637. DOI: 10.1016/j.semarthrit.2018.05.011. View

10.

Kamata M, Tada Y . Safety of biologics in psoriasis. J Dermatol. 2017; 45(3):279-286. DOI: 10.1111/1346-8138.14096. View

11.

Khattri S, Goldblum O, Solotkin K, Amir Y, Min M, Ridenour T . Early Onset of Clinical Improvement with Ixekizumab in a Randomized, Open-label Study of Patients with Moderate-to-severe Plaque Psoriasis. J Clin Aesthet Dermatol. 2018; 11(5):33-37. PMC: 5955632. View

12.

Armstrong E, Harskamp C, Armstrong A . Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013; 2(2):e000062. PMC: 3647278. DOI: 10.1161/JAHA.113.000062. View

13.

Reich K, Armstrong A, Langley R, Flavin S, Randazzo B, Li S . Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019; 394(10201):831-839. DOI: 10.1016/S0140-6736(19)31773-8. View

14.

Feagan B, Sandborn W, Gasink C, Jacobstein D, Lang Y, Friedman J . Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016; 375(20):1946-1960. DOI: 10.1056/NEJMoa1602773. View

15.

Furue M, Kadono T . "Inflammatory skin march" in atopic dermatitis and psoriasis. Inflamm Res. 2017; 66(10):833-842. DOI: 10.1007/s00011-017-1065-z. View

16.

Papp K, Lebwohl M . Onset of Action of Biologics in Patients With Moderate-to-Severe Psoriasis. J Drugs Dermatol. 2018; 17(3):247-250. View

17.

Cheuk S, Schlums H, Gallais Serezal I, Martini E, Chiang S, Marquardt N . CD49a Expression Defines Tissue-Resident CD8 T Cells Poised for Cytotoxic Function in Human Skin. Immunity. 2017; 46(2):287-300. PMC: 5337619. DOI: 10.1016/j.immuni.2017.01.009. View

18.

Foley P, Gordon K, Griffiths C, Wasfi Y, Randazzo B, Song M . Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Dermatol. 2018; 154(6):676-683. PMC: 6145649. DOI: 10.1001/jamadermatol.2018.0793. View

19.

Elnabawi Y, Dey A, Goyal A, Groenendyk J, Chung J, Belur A . Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res. 2019; 115(4):721-728. PMC: 6432047. DOI: 10.1093/cvr/cvz009. View

20.

Blauvelt A, Papp K, Lebwohl M, Green L, Hsu S, Bhatt V . Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3). J Am Acad Dermatol. 2017; 77(2):372-374. DOI: 10.1016/j.jaad.2017.03.026. View